These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 33006693)

  • 1. Simultaneous triple cancer of the esophagus, pancreas and rectum treated with multimodal strategies: a case report.
    Imamura H; Hirose H; Endo S; Hashimoto Y; Takeda M; Kidogami S; Mokutani Y; Kishimoto T; Yoshioka S; Tamura S; Sasaki Y
    Surg Case Rep; 2020 Oct; 6(1):259. PubMed ID: 33006693
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A case of successful conversion surgery for locally advanced pancreatic cancer with synchronous triple cancer of the lung and esophagus: a case report.
    Mita J; Iguchi T; Iseda N; Takada K; Hirose K; Miura N; Honboh T; Emi Y; Akashi T; Kato S; Sadanaga N; Matsuura H
    Surg Case Rep; 2022 Jan; 8(1):19. PubMed ID: 35067787
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synchronous double primary malignancies of the pancreatic body and extrahepatic bile duct treated with pancreatoduodenectomy and splenic artery resection following neoadjuvant chemotherapy with gemcitabine plus nab-paclitaxel: a case report.
    Murokawa T; Okabayashi T; Sui K; Tabuchi M; Iwata J
    Surg Case Rep; 2022 Feb; 8(1):29. PubMed ID: 35171354
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neoadjuvant plus adjuvant or only adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer - the NEONAX trial (AIO-PAK-0313), a prospective, randomized, controlled, phase II study of the AIO pancreatic cancer group.
    Ettrich TJ; Berger AW; Perkhofer L; Daum S; König A; Dickhut A; Wittel U; Wille K; Geissler M; Algül H; Gallmeier E; Atzpodien J; Kornmann M; Muche R; Prasnikar N; Tannapfel A; Reinacher-Schick A; Uhl W; Seufferlein T
    BMC Cancer; 2018 Dec; 18(1):1298. PubMed ID: 30594153
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparisons of different neoadjuvant chemotherapy regimens with or without stereotactic body radiation therapy for borderline resectable pancreatic cancer: study protocol of a prospective, randomized phase II trial (BRPCNCC-1).
    Gao S; Zhu X; Shi X; Cao K; Bian Y; Jiang H; Wang K; Guo S; Zhang H; Jin G
    Radiat Oncol; 2019 Mar; 14(1):52. PubMed ID: 30917842
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preoperative chemotherapy, radiotherapy, and surgical resection of locally advanced pancreatic cancer.
    Wanebo HJ; Glicksman AS; Vezeridis MP; Clark J; Tibbetts L; Koness RJ; Levy A
    Arch Surg; 2000 Jan; 135(1):81-7; discussion 88. PubMed ID: 10636353
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical impact of multimodal treatment including chemoradiotherapy, conversion surgery and postoperative chemotherapy for borderline resectable and unresectable locally advanced pancreatic cancer without disease progression after gemcitabine plus nab-paclitaxel.
    Umezawa R; Mizuma M; Nakagawa K; Yamamoto T; Takahashi N; Suzuki Y; Kishida K; Omata S; Unno M; Jingu K
    Pancreatology; 2023 Sep; 23(6):650-656. PubMed ID: 37453848
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Curative two-stage resection for synchronous triple cancers of the esophagus, colon, and liver: Report of a case.
    Akiyama Y; Iwaya T; Konosu M; Shioi Y; Endo F; Katagiri H; Nitta H; Kimura T; Otsuka K; Koeda K; Kashiwaba M; Mizuno M; Kimura Y; Sasaki A
    Int J Surg Case Rep; 2015; 13():1-4. PubMed ID: 26074482
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Perioperative or only adjuvant gemcitabine plus nab-paclitaxel for resectable pancreatic cancer (NEONAX)-a randomized phase II trial of the AIO pancreatic cancer group.
    Seufferlein T; Uhl W; Kornmann M; Algül H; Friess H; König A; Ghadimi M; Gallmeier E; Bartsch DK; Lutz MP; Metzger R; Wille K; Gerdes B; Schimanski CC; Graupe F; Kunzmann V; Klein I; Geissler M; Staib L; Waldschmidt D; Bruns C; Wittel U; Fichtner-Feigl S; Daum S; Hinke A; Blome L; Tannapfel A; Kleger A; Berger AW; Kestler AMR; Schuhbaur JS; Perkhofer L; Tempero M; Reinacher-Schick AC; Ettrich TJ
    Ann Oncol; 2023 Jan; 34(1):91-100. PubMed ID: 36209981
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized phase II study of gemcitabine and S-1 combination therapy versus gemcitabine and nanoparticle albumin-bound paclitaxel combination therapy as neoadjuvant chemotherapy for resectable/borderline resectable pancreatic ductal adenocarcinoma (PDAC-GS/GA-rP2, CSGO-HBP-015).
    Yamada D; Kobayashi S; Takahashi H; Akita H; Yamada T; Asaoka T; Shimizu J; Takeda Y; Yokoyama S; Tsujie M; Tomokuni A; Tanemura M; Morimoto O; Murakami M; Kim Y; Nakahira S; Hama N; Sugimoto K; Hashimoto K; Doki Y; Eguchi H
    Trials; 2021 Aug; 22(1):568. PubMed ID: 34446057
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immediate surgery compared with short-course neoadjuvant gemcitabine plus capecitabine, FOLFIRINOX, or chemoradiotherapy in patients with borderline resectable pancreatic cancer (ESPAC5): a four-arm, multicentre, randomised, phase 2 trial.
    Ghaneh P; Palmer D; Cicconi S; Jackson R; Halloran CM; Rawcliffe C; Sripadam R; Mukherjee S; Soonawalla Z; Wadsley J; Al-Mukhtar A; Dickson E; Graham J; Jiao L; Wasan HS; Tait IS; Prachalias A; Ross P; Valle JW; O'Reilly DA; Al-Sarireh B; Gwynne S; Ahmed I; Connolly K; Yim KL; Cunningham D; Armstrong T; Archer C; Roberts K; Ma YT; Springfeld C; Tjaden C; Hackert T; Büchler MW; Neoptolemos JP;
    Lancet Gastroenterol Hepatol; 2023 Feb; 8(2):157-168. PubMed ID: 36521500
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term effects of multimodal treatment for patients with resectable carcinoma of the pancreas.
    Okabayashi T; Nishimori I; Nishioka A; Yamashita K; Sugimoto T; Dabanaka K; Maeda H; Kohsaki T; Ogawa Y; Kobayashi M; Onishi S; Hanazaki K
    Oncol Rep; 2008 Sep; 20(3):651-6. PubMed ID: 18695919
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Curative resection after chemotherapy and chemoradiotherapy for postoperative recurrence of pancreatic tail cancer in the abdominal wall: a case report.
    Iio S; Hozaka Y; Tanoue K; Idichi T; Fukuda K; Nakashima T; Yasudome R; Yamasaki Y; Kawasaki Y; Arigami T; Nakajo A; Higashi M; Mataki Y; Kurahara H; Ohtsuka T
    Surg Case Rep; 2022 May; 8(1):101. PubMed ID: 35585274
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Triple modal treatment comprising with proton beam radiation, hyperthermia, and gemcitabine/nab-paclitaxel for locally advanced pancreatic cancer: a phase I/II study protocol (TT-LAP trial).
    Shimomura O; Endo M; Makishima H; Yamada T; Hashimoto S; Numajiri H; Miyazaki Y; Doi M; Furuya K; Takahashi K; Moriwaki T; Hasegawa N; Yamamoto Y; Niisato Y; Kobayashi M; Mizumoto M; Nakai K; Saito T; Hoshiai S; Saida T; Mathis BJ; Mori K; Nakajima T; Tsuchiya K; Sakurai H; Oda T
    BMC Cancer; 2023 Jul; 23(1):624. PubMed ID: 37403011
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [A Case of Surgical Resection of Anaplastic Carcinoma of the Pancreas(Pleomorphic Cell Type)with Poor Response to Neoadjuvant Chemotherapy].
    Naruse K; Maruyama T; Aono T; Okada T; Suzuki S; Kaneko K; Sato T; Muto I; Hasegawa M; Ichikawa H; Takizawa K; Nakano M; Shimada Y; Sakata J; Wakai T
    Gan To Kagaku Ryoho; 2021 Dec; 48(13):1601-1603. PubMed ID: 35046269
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase 2 study of preoperative chemotherapy with nab-paclitaxel and gemcitabine followed by chemoradiation for borderline resectable or node-positive pancreatic ductal adenocarcinoma.
    Chen EY; Kardosh A; Nabavizadeh N; Foster B; Mayo SC; Billingsley KG; Gilbert EW; Lanciault C; Grossberg A; Bensch KG; Maynard E; Anderson EC; Sheppard BC; Thomas CR; Lopez CD; Vaccaro GM;
    Cancer Med; 2023 Jun; 12(12):12986-12995. PubMed ID: 37132281
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Salvage esophagectomy after definitive chemoradiotherapy for synchronous double cancers of the esophagus and head-and-neck.
    Yoshida R; Morita M; Ando K; Masuda T; Saeki H; Oki E; Sadanaga N; Nakashima T; Kakeji Y; Maehara Y
    Dis Esophagus; 2010 Jan; 23(1):59-63. PubMed ID: 19392844
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preservation of remnant esophagus during total pharyngolaryngectomy in a patient with previous subtotal esophagectomy: a case report.
    Oshikiri H; Okamoto H; Taniyama Y; Ishii R; Ohkoshi A; Kurosawa K; Unno M; Kamei T
    Surg Case Rep; 2023 Mar; 9(1):42. PubMed ID: 36941470
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Searching for novel multimodal treatments in oligometastatic pancreatic cancer.
    Filippini DM; Grassi E; Palloni A; Carloni R; Casadei R; Ricci C; Serra C; Ercolani G; Brandi G; Di Marco M
    BMC Cancer; 2020 Mar; 20(1):271. PubMed ID: 32228504
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intensified Neoadjuvant Chemotherapy with Nab-Paclitaxel plus Gemcitabine Followed by FOLFIRINOX in a Patient with Locally Advanced Unresectable Pancreatic Cancer.
    Kunzmann V; Herrmann K; Bluemel C; Kapp M; Hartlapp I; Steger U
    Case Rep Oncol; 2014 Sep; 7(3):648-55. PubMed ID: 25408659
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.